No clinical trials have tested ozone therapy specifically for PTSD. The theoretical basis relies on ozone’s anti-inflammatory and neuromodulatory properties, but the evidence trail ends at animal studies and extrapolation from other conditions. By contrast, HBOT has an actual RCT in PTSD: a 2022 trial of military veterans showed 60 sessions produced significant symptom improvement versus sham, with a large effect size.
PTSD and the Brain
PTSD is a condition rooted in measurable brain changes. Neuroimaging studies consistently show structural and functional abnormalities in three key brain regions:
- Amygdala. Hyperactive in PTSD, driving exaggerated fear responses and hypervigilance.
- Prefrontal cortex. Underactive, impairing the ability to regulate emotional responses and distinguish past threats from present safety.
- Hippocampus. Reduced volume, affecting memory processing and the ability to contextualize traumatic memories as past events rather than ongoing threats.4
Neuroinflammation plays a role in these changes. Studies show elevated inflammatory markers (CRP, IL-6, TNF-alpha) in PTSD patients, along with activated microglia and increased blood-brain barrier permeability. This inflammatory state impairs neuroplasticity and may prevent the brain from naturally recovering from trauma.
The Theoretical Case for Ozone Therapy
Ozone therapy’s proposed relevance to PTSD rests on several biological mechanisms:
| Mechanism | What Ozone Does | PTSD Relevance | Evidence Level |
|---|---|---|---|
| Anti-inflammatory | Modulates NF-kB, activates Nrf2, reduces pro-inflammatory cytokines | Neuroinflammation is elevated in PTSD | Established for ozone (not tested in PTSD) |
| Improved oxygenation | Increases oxygen delivery to tissues via 2,3-DPG | Brain hypoperfusion observed in PTSD | Established for ozone (not tested in PTSD) |
| Oxidative preconditioning | Trains antioxidant systems to handle oxidative stress | Oxidative stress contributes to neuronal damage in PTSD | Preclinical only |
| Mitochondrial support | May improve mitochondrial function and energy production | Mitochondrial dysfunction is linked to anxiety and PTSD | Preclinical only |
Each of these mechanisms is documented for ozone therapy in general contexts. The problem is that none have been tested in PTSD patients. The leap from “ozone reduces inflammation” to “ozone treats PTSD” requires clinical evidence that does not exist.
Why There Is No Evidence
Several factors explain why ozone therapy for PTSD has no published research:
- PTSD research funding flows primarily to psychotherapy, pharmaceuticals, and more established biological interventions (HBOT, ketamine, MDMA, TMS).
- Ozone therapy lacks the institutional support and pharmaceutical backing needed to fund expensive clinical trials for psychiatric conditions.
- The regulatory environment around ozone therapy is complex, making it harder to gain IRB approval for psychiatric applications.
- HBOT, which shares some mechanistic overlap (improved oxygenation, reduced inflammation), is already being studied for PTSD and attracts the research attention that might otherwise go to ozone.
“In a randomized controlled trial, 60 sessions of HBOT produced significant improvement in treatment-resistant PTSD in veterans, with a large effect size of 1.64, and benefits that persisted at 2-year follow-up (Doenyas-Barak et al., 2022). No comparable evidence exists for ozone therapy.”
HBOT vs. Ozone Therapy for PTSD
If you are considering an oxygen-based therapy for PTSD, HBOT has a substantially stronger evidence base:
| Factor | Ozone Therapy | HBOT |
|---|---|---|
| Published PTSD trials | None | Multiple (including RCTs) |
| Neuroimaging evidence | None for PTSD | fMRI and DTI showing improved brain structure and function2 |
| Long-term follow-up | None | Benefits persist at 2 years with improved social functioning5 |
| Ongoing research | None registered | $28M USF trial enrolling 400+ veterans3 |
| Cost per session | $100-300 | $200-400 |
| Typical protocol | No established protocol | 40-60 sessions (based on trial data) |
The Doenyas-Barak RCT is particularly notable: veterans with treatment-resistant PTSD received 60 daily HBOT sessions, and their CAPS-5 scores (the gold standard PTSD measure) improved significantly with a large effect size of 1.64. Brain imaging confirmed structural and functional improvements in the prefrontal cortex, hippocampus, and insula.2
At 2-year follow-up, improvements persisted. Working rates increased from 41% to 73%, partnership rates rose from 46% to 77%, and benzodiazepine and cannabis use decreased.5
Cost and Realistic Expectations
Ozone therapy sessions for any application typically cost $100-300 each. Without an established protocol for PTSD, practitioners may recommend anywhere from 10 to 30 sessions, putting the total cost at $1,000-9,000 out of pocket. Insurance does not cover ozone therapy for PTSD.
For comparison, HBOT for PTSD costs $200-400 per session, with the evidence-based protocols using 40-60 sessions ($8,000-24,000 total). While more expensive overall, HBOT has the clinical data to support its use.
Anyone considering ozone therapy for PTSD should have realistic expectations: there is no clinical evidence that it works for this condition. It should never replace evidence-based PTSD treatments, which include trauma-focused cognitive behavioral therapy (CBT), eye movement desensitization and reprocessing (EMDR), prolonged exposure therapy, and FDA-approved medications (sertraline, paroxetine).
The Bottom Line
Ozone therapy for PTSD is a theoretical application with zero clinical evidence. The biological rationale is plausible but unproven. If neuroinflammation and impaired brain oxygenation contribute to PTSD (and evidence suggests they do), then therapies that address these factors could theoretically help. But “could theoretically help” is not the same as “has been shown to help.”
For oxygen-based PTSD treatment, HBOT has meaningful clinical evidence, including randomized controlled trials with neuroimaging confirmation and long-term follow-up data. For PTSD treatment in general, trauma-focused psychotherapy and FDA-approved medications remain the evidence-based standard of care.
Related Articles
References
- Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front Chem. 2015;3:4. DOI: 10.3389/fchem.2015.00004
- Doenyas-Barak K, Catalogna M, Kutz I, et al. Hyperbaric oxygen therapy improves symptoms, brain’s microstructure and functionality in veterans with treatment resistant post-traumatic stress disorder. PLoS ONE. 2022;17(2):e0264161. DOI: 10.1371/journal.pone.0264161
- USF Health. Landmark $28 million HBOT clinical trial for veterans with TBI/PTSD. 2025.
- Pitman RK, Rasmusson AM, Koenen KC, et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci. 2012;13(11):769-787. DOI: 10.1038/nrn3339
- Doenyas-Barak K, Catalogna M, Kutz I, et al. Long-term follow-up of hyperbaric oxygen therapy for post-traumatic stress disorder in veterans. Mil Med. 2022. DOI: 10.1093/milmed/usac360
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
